Bispecific Antibodies in DLBCL Trials

EP: 1.Bispecific Antibodies in DLBCL: Therapeutic Potential

EP: 2.Efficacy Insights on Bispecific Antibodies in DLBCL

Now Viewing

EP: 3.Bispecific Antibodies in DLBCL Trials

EP: 4.Bispecific Antibodies in DLBCL: Patient Response

EP: 5.Future Insights on Bispecific Therapies

EP: 6.Overcoming DLBCL Treatment Hurdles

EP: 7.Patient Education and Monitoring in DLBCL Treatment

EP: 8.Implementing Bispecific Treatments

EP: 9.Bispecific Toxicity Management in DLBCL Care

EP: 10.Multidisciplinary Bispecific Care

EP: 11.Pharmacists: Bispecifics and Operational Role

EP: 12.Strategies for Reducing Bispecific Therapy Toxicities

EP: 13.Unmet Needs in Bispecific Therapy Access

EP: 14.Implementing Bispecific Antibodies in Lymphoma Care

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this discussion, Mahmoudjafari and Mancini review the clinical trials leading to the approval of epcoritamab and glofitamab therapies. Epcoritamab, based on the EPCORE NHL-1 trial, demonstrated a 63% overall response rate and an approximately 40% complete response rate, with a 12-month median duration of response. Glofitamab, from the NP30179 trial, showed a 52% overall response rate and a 39% complete response rate, with an 18.5-month median duration of response.

Both therapies raised questions about response rates in patients with prior chimeric antigen receptor T-cell therapy. Cytokine release syndrome (CRS) was a notable toxicity, with epcoritamab at 50% overall CRS and glofitamab at 70%. Neurotoxicity syndrome was rare, with 6% for epcoritamab and 8% for glofitamab. The focus remains on CRS, and further data is awaited to deepen understanding.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.